3/27
08:30 am
cmmb
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
High
Report
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
3/6
08:00 am
cmmb
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
Medium
Report
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
3/3
08:34 am
cmmb
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
High
Report
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/3
08:00 am
cmmb
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
High
Report
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
2/20
01:28 pm
cmmb
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its price target raised by analysts at Maxim Group from $4.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its price target raised by analysts at Maxim Group from $4.00 to $7.00. They now have a "buy" rating on the stock.
2/19
07:00 am
cmmb
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
Low
Report
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
2/3
08:13 am
cmmb
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/3
07:00 am
cmmb
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Low
Report
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/30
05:31 pm
cmmb
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight
Low
Report
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight
1/30
05:31 pm
cmmb
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight
Low
Report
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight